CN114796325A - 一种治疗膝骨关节炎的中药组合物及其制备方法与应用 - Google Patents
一种治疗膝骨关节炎的中药组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN114796325A CN114796325A CN202210572729.0A CN202210572729A CN114796325A CN 114796325 A CN114796325 A CN 114796325A CN 202210572729 A CN202210572729 A CN 202210572729A CN 114796325 A CN114796325 A CN 114796325A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 23
- 208000003947 Knee Osteoarthritis Diseases 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 15
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 15
- 244000018716 Impatiens biflora Species 0.000 claims abstract description 14
- 235000015912 Impatiens biflora Nutrition 0.000 claims abstract description 14
- 235000005155 Tanacetum balsamita Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 241000903946 Clematidis Species 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 13
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 12
- 241000123589 Dipsacus Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000006208 topical dosage form Substances 0.000 claims 1
- 230000036407 pain Effects 0.000 abstract description 21
- 208000002193 Pain Diseases 0.000 abstract description 20
- 210000000629 knee joint Anatomy 0.000 abstract description 16
- 208000024891 symptom Diseases 0.000 abstract description 16
- 206010061218 Inflammation Diseases 0.000 abstract description 15
- 230000004054 inflammatory process Effects 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 238000003958 fumigation Methods 0.000 abstract description 7
- 230000008407 joint function Effects 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 230000008338 local blood flow Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 238000000554 physical therapy Methods 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 30
- 230000008961 swelling Effects 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 210000002435 tendon Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 241001256368 Clematis chinensis Species 0.000 description 4
- 206010023232 Joint swelling Diseases 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000005065 subchondral bone plate Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 3
- 206010023230 Joint stiffness Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001480035 Epidermophyton Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010060968 Arthritis infective Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗膝骨关节炎的中药组合物及其制备方法与应用,属于中药技术领域。该中药组合物由以下重量份的原料药制成:凤仙透骨草4~12份、艾叶4~12份、鸡血藤4~12份、威灵仙5~10份、黄芪8~18份、淫羊藿4~12份、续断4~12份、红花1~4份、伸筋草4~12份。该中药组合物可以通过熏蒸、溻渍、泡浴等外用方式进行治疗膝骨关节炎,通过药物透皮吸收和水的温热理疗作用,药物可直接作用于膝关节局部,使局部皮肤温度升高,扩张血管,改善局部血液循环,促进瘀血吸收、炎症消散,加速新陈代谢,促进水肿消退及组织修复,缓解患者炎症状态。从而减轻患者疼痛症状,改善关节功能。
Description
技术领域
本发明涉及中药领域,具体涉及一种治疗膝骨关节炎的中药组合物及其制备方法与应用。
背景技术
膝骨关节炎(knee osteoarthritis,KOA)是一种严重影响中老年人生活质量的慢性退行性疾病,属中医“痹证”“痿证”范畴。本病是一种多因素导致的全关节疾病,病因尚不明确,其发生与年龄、肥胖、炎症、创伤及遗传因素等有关。病理特点为关节软骨破坏、软骨下骨硬化或囊性变、关节边缘骨质增生、滑膜病变、关节囊挛缩、韧带松弛或挛缩、肌肉萎软无力等。现有西医技术根据患者不同情况采用药物治疗和手术治疗。药物多以口服消炎、镇痛药、以及关节腔注射玻璃酸钠、生长因子、或糖皮质激素为主。中医的治疗则是提供以中草药口服、中草药外用、针灸与推拿等相结合的综合服务手段。
西医的方法多以手术治疗、药物口服、以及膝关节腔药物注射为主。而治疗该病的中药内服药刺激肠胃,且没有直接作用于患处,不能迅速缓解患者疼痛、肿胀等症状。同时口服药物常有一些不良反应,而膝骨关节炎患者大多年龄较大,常有慢性基础疾病,平素常口服多种药物治疗,增加药物不但增加胃肠道负担,也使药物间相互作用的概率增加,患者难以长期服用,而部分患者常因惧怕疼痛难以耐受针灸、针刀等疗法。
发明内容
本发明的目的在于克服现有技术的不足,提供一种治疗膝骨关节炎的中药组合物及其制备方法与应用。
为实现上述目的,本发明采取的技术方案为:第一方面,提供一种治疗膝骨关节炎的中药组合物,所述中药组合物由以下重量份的原料药制成:凤仙透骨草4~12份、艾叶4~12份、鸡血藤4~12份、威灵仙5~10份、黄芪8~18份、淫羊藿4~12份、续断4~12份、红花1~4份、伸筋草4~12份。
本发明将上述原料组合成治疗膝骨关节炎的中药组合物,该中药组合物可以通过熏蒸、溻渍、泡浴等外用方式进行治疗膝骨关节炎,通过药物透皮吸收和水的温热理疗作用,药物可直接作用于膝关节局部,使局部皮肤温度升高,扩张血管,改善局部血液循环,促进瘀血吸收、炎症消散,加速新陈代谢,促进水肿消退及组织修复,缓解患者炎症状态。从而减轻患者疼痛症状,改善关节功能。
方中各种中药原料的药理疗效如下:
凤仙透骨草:甘、微苦、温。归肝经,活血消肿止痛、祛风。现代药理研究也证实具有消炎、抗菌作用。凤仙花的鲜花汁,对红色表皮癣菌,堇色毛癣菌及腹股沟表皮癣菌,专夫曼高尔夫表皮癣菌均有抑制作用。
艾叶:辛、苦、温,归肝、脾、肾经。温经止血、散寒止痛、祛湿止痒、调经安胎。现代药理表明艾叶具有镇痛、抗炎、抗菌,提高巨噬细胞的吞噬功能作用。
鸡血藤:苦、甘、温,归肝经,活血补血、舒筋活络。现代药理显示鸡血藤提取物通过提高抗氧化物酶活力,从而清楚过量氧自由基以达到抗氧化、抗炎作用。
威灵仙:辛、咸、温,归膀胱经,祛风湿、通筋络、消痰水、治骨鲠。威灵仙在现代药理中认为其提取物威灵仙总皂苷起抗炎镇痛作用,威灵仙总皂苷能显著降低炎症因子水平,减轻关节肿胀,同时活化抗氧化作用。
黄芪:甘、微温,归脾、肺经,补气升阳、益卫固表、利水消肿、托疮生肌。现代药理研究表明黄芪中含有黄芪多糖、黄芪甲苷等,可降糖、降脂、改善胰岛素抵抗、抑制炎症反应、降低氧化应激反应、增强免疫功能。
淫羊藿:辛、甘、温,归肝、肾经,温肾补阳、强筋骨、祛风湿。现代药理研究表明淫羊藿苷具有改善骨代谢、抗炎、抗氧化应激、抗抑郁和抗肿瘤等活性。
续断:苦、甘辛、微温,归肝、肾经补肝肾、强筋骨、止血安胎、疗伤续断。现代药理作用包括促骨形成、增强免疫与抗菌消炎等。
红花:辛、温,归心、肝经,活血通经、祛瘀止痛。清热燥湿、杀虫、利尿。现代药理研究亦表明红花具有抗炎和提高组织耐缺氧能力,改善氧自由基,减轻神经细胞的损伤,亦能明显抑制致炎物质组织胺导致的毛细血管通透性增高等作用。
伸筋草:苦、辛、温,归肝经,祛风除湿、舒筋活血。现代药理研究认为伸筋草具有抗炎、镇痛、抗氧化、抗血小板凝集等多种功效。
全方活血化瘀通络、温经散寒解痉之效,方中风仙透骨草、伸筋草、红花、鸡血藤等均被现代药理学证实对关节功能恢复有利。其中,透骨草、伸筋草具有镇痛及抗炎作用;红花可抑制血小板聚集,有效改善膝关节局部微循环,促进关节组织再生;鸡血藤可加强舒筋活络,对关节屈曲舒展有利。诸药结合可从根本上改善患者的关节功能。结合熏蒸疗法,通过熏蒸治疗机可直接将汤剂转化为蒸汽作用于膝关节,具有舒筋通络、活血化瘀的效果,同时药物直接作用于患处,充分发挥治疗作用,可降低患者神经末梢兴奋,缓解韧带、肌肉组织僵直、痉挛的症状,改善患处血流,继而有利于膝关节功能的恢复。
作为本发明中药组合物的可选方案,所述中药组合物由以下重量份的原料药制成:凤仙透骨草4~8份、艾叶4~8份、鸡血藤4~8份、威灵仙5~8份、黄芪12~18份、淫羊藿4~10份、续断4~10份、红花1~3份、伸筋草4~10份。发明人发现,在上述配比范围内,中药组合物具有更好的治疗作用。
作为本发明中药组合物的可选方案,所述中药组合物由以下重量份的原料药制成:凤仙透骨草4份、艾叶4份、鸡血藤4份、威灵仙5份、黄芪8份、淫羊藿4份、续断4份、红花1份、伸筋草4份。发明人发现,在上述配比范围内,中药组合物治疗膝骨关节炎的作用最佳。
作为本发明中药组合物的可选方案,所述中药组合物为外用剂型。
作为本发明中药组合物的可选方案,所述外用剂型为外用液体制剂、贴剂、软膏剂、凝胶剂、糊剂、涂膜剂、巴布剂、外用气雾剂中的一种。
对于本发明所述的中药组合物的外用剂型没有特别的限制,可以是任何适用于哺乳动物外治的剂型;优选的,所述的外用剂型可选自:外用液体制剂、贴剂、软膏剂、凝胶剂、糊剂、涂膜剂、巴布剂或外用气雾剂。从易于制备、给药的立场看,优选为液体外用制剂,尤其是溶液、洗剂。
作为本发明中药组合物的可选方案,所述中药组合物含有药学上可接受的载体。
第二方面,提供一种中药组合物的制备方法,包括以下步骤:按重量比将各原料药分别采取水提或乙醇回流,所得提取物加上药学上常用的辅料或辅助性成分,加工成制剂。
第三方面,提供所述中药组合物在制备治疗膝骨关节炎药物中的应用。
与现有技术相比,本发明的有益效果为:本发明的中药组合物可以有效减轻患者疼痛,改善关节功能,同时避免内服药物引起的胃肠带不舒等副作用。本发明的中药组合物成本低,且易于使用。
具体实施方式
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步的说明。
实施例1
本实施例用于说明本发明中药组合物的制备。
按重量份配比,称取凤仙透骨草4份、艾叶4份、鸡血藤4份、威灵仙5份、黄芪8份、淫羊藿4份、续断4份、红花1份、伸筋草4份,混合后加入中药原料总质量8倍的水,加热煎煮,沸后计时,煎煮时间为半小时,过滤后所得药汁,即为治疗膝骨关节炎的中药外用液体制剂。
实施例2
本实施例用于说明本发明中药组合物的制备。
按重量份配比,称取凤仙透骨草6份、艾叶6份、鸡血藤6份、威灵仙6份、黄芪12份、淫羊藿6份、续断6份、红花3份、伸筋草6份,混合后加入中药原料总质量8倍的水,加热煎煮,沸后计时,煎煮时间为半小时,过滤后所得药汁,即为治疗膝骨关节炎的中药外用液体制剂。
实施例3
本实施例用于说明本发明中药组合物的制备。
按重量份配比,称取凤仙透骨草8份、艾叶8份、鸡血藤8份、威灵仙8份、黄芪15份、淫羊藿8份、续断8份、红花2份、伸筋草8份,混合后加入中药原料总质量12倍的水,加热煎煮,沸后计时,煎煮时间为半小时,过滤后所得药汁,即为治疗膝骨关节炎的中药外用液体制剂。
实施例4
本实施例用于说明本发明中药组合物的制备。
按重量份配比,称取凤仙透骨草12份、艾叶12份、鸡血藤12份、威灵仙10份、黄芪18份、淫羊藿12份、续断12份、红花4份、伸筋草12份。混合后加入中药原料总质量16倍的水,加热煎煮,沸后计时,煎煮时间为半小时,过滤后所得药汁,即为治疗膝骨关节炎的中药外用液体制剂。
效果例1
本效果例用于说明本发明中药组合物的治疗效果。
(一)实验方法
将符合纳入标准的病人116例,随机分为两组,每组58人,其中观察组患者均采用实施例1的外用液体制剂对膝关节进行熏蒸,联合口服盐酸氨基葡萄糖胶囊进行治疗;对照组患者均采用口服盐酸氨基葡萄糖胶囊进行治疗;外用液体制剂的使用方法为:每日1次,每次半小时;盐酸氨基葡萄糖胶囊的使用方法为:一日2次,一次1粒(75毫克);各组治疗用药共6周,观察各组治疗前后湿疹症状积分的变化,并评价其疗效及安全性。
1、患者纳入标准:
患者临床症状为局部可见轻度肿胀、活动时伴有摩擦声,严重者可见肌肉萎缩;X线检查显示骨质疏松、关节面不规则、软骨下骨硬化;患者年龄在30-80岁之间,病程>3个月,近1个月内未用其他方式治疗或服用其他药物者;自愿参与研究,签署知情同意书,可以配合治疗者。
2、患者排除标准:
(1)合并膝关节感染及免疫类疾病者;
(2)膝关节有过重大创伤;
(3)膝周皮肤有感染或皮肤病者;
(4)患有结核、肿瘤或有精神病史;
(5)治疗过程中使用其他药物者。
3、剔除、脱落及终止实验标准:
详细记录观察对象终止临床试验的原因及时间。达到以下6条中任意1条标准者,予以剔除:
(1)导致严重不良事件;
(2)服药过程中受试者出现原有病情严重进展、合并其他严重疾病或严重不良反应;
(3)观察对象依从性低,未遵医嘱者;
(4)受试者因个人因素自行退出者;
(5)治疗期间自行服用其他药物,干扰研究结果者;
(6)失访及无法随访者。
(二)疗效评价指标及评价标准
1、疗效性指标:(1)改善程度及有效率;(2)膝骨关节炎症候积分。
2、疗效评价标准:采用骨关节炎指数(WOMAC)对三组患者关节僵硬程度及功能进行评价,WOMAC评分主要包括疼痛、僵硬、关节功能3个方面,项目共计24个,每个项目分值0~4分,总分0~96分,分数越高说明症状越严重。治疗前后各评价1次。
中医证候疗效指标=(治疗前积分-治疗后积分)/治疗前积分×100%;
(1)显效:膝关节无压痛、疼痛及肿胀,偶有摩擦音,活动正常,n%≥70%;
(2)有效:膝关节疼痛、肿胀,压痛减轻,有摩擦音,活动有所改善,软骨下骨硬化,30%≤n%<70%;
(3)无效:膝关节压痛、疼痛及肿胀等症状无改善或加重,软骨下骨硬化,n%<30%;
(4)显效和有效统称为总有效率。
3、应用数据处理与统计学分析
Excel整理数据库,应用SPSS20.0统计软件进行统计分析,所有数据均以X±S表示。组间比较采用t检验,计数资料的比较采用χ2检验,P<0.05为差异有统计学意义。
(三)实验结果
治疗前,对各组症候总积分进行比较,得出P>0.05,差异无统计学意义,表明各组症候总积分具有可比性。各组治疗前后中医症候总积分比较结果如表1所示:
根据中医症候疗效标准,治疗后各组总有效率如表2所示:
表2各组治疗后总有效率比较[例(%)]
组别 | 例数 | 痊愈 | 显效 | 有效 | 无效 | 总计 |
对照组 | 58 | 23(39.66) | 16(27.59) | 10(17.24) | 9(15.51) | 49(84.48) |
观察组 | 58 | 31(53.45) | 15(25.86) | 10(17.24) | 2(3.45) | 56(96.55) |
从表2的结果可知,本发明的中药组合物治疗膝骨关节炎的有效率为96.55%,高于对照组,说明本发明的中药组合物对膝骨关节炎具有显著的作用,并且研究发现,本发明的中药组合物无任何明显的副作用。
临床病例节选:
姚某,男,65岁,右膝关节肿痛4个月,加重1周,外用药熏蒸治疗1月后,其关节疼痛、肿胀情况改善,日常活动受限好转。
周某,女,55岁,左膝关节肿痛3年,加重1月。外用药熏蒸治疗6周后,其关节疼痛、肿胀、僵硬情况改善,WOMAC评分结果显示明显好转。
贺某,女,40岁,左膝关节肿痛1年,加重1周。外用药熏蒸治疗3周后,其关节疼痛、肿胀、僵硬情况改善,关节压痛减轻、偶有摩擦音。
蒋某,男,52岁,右膝关节因运动损伤肿痛2年,加重1月余,外用药熏蒸治疗6周后,其关节疼痛、肿胀、僵硬情况改善,关节压痛减轻,活动受限情况好转。
最后所应当说明的是,以上实施例用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者同等替换,而不脱离本发明技术方案的实质和范围。
Claims (8)
1.一种治疗膝骨关节炎的中药组合物,其特征在于,所述中药组合物由以下重量份的原料药制成:凤仙透骨草4~12份、艾叶4~12份、鸡血藤4~12份、威灵仙5~10份、黄芪8~18份、淫羊藿4~12份、续断4~12份、红花1~4份、伸筋草4~12份。
2.如权利要求1所述的中药组合物,其特征在于,所述中药组合物由以下重量份的原料药制成:凤仙透骨草4~8份、艾叶4~8份、鸡血藤4~8份、威灵仙5~8份、黄芪12~18份、淫羊藿4~10份、续断4~10份、红花1~3份、伸筋草4~10份。
3.如权利要求1所述的中药组合物,其特征在于,所述中药组合物由以下重量份的原料药制成:凤仙透骨草4份、艾叶4份、鸡血藤4份、威灵仙5份、黄芪8份、淫羊藿4份、续断4份、红花1份、伸筋草4份。
4.如权利要求1-3任一项所述的中药组合物,其特征在于,所述中药组合物为外用剂型。
5.如权利要求4所述的中药组合物,其特征在于,所述外用剂型为外用液体制剂、贴剂、软膏剂、凝胶剂、糊剂、涂膜剂、巴布剂、外用气雾剂中的一种。
6.如权利要求5所述的中药组合物,其特征在于,所述中药组合物含有药学上可接受的载体。
7.一种如权利要求1-6任一项所述中药组合物的制备方法,其特征在于,包括以下步骤:按重量比将各原料药分别采取水提或乙醇回流,所得提取物加上药学上常用的辅料或辅助性成分,加工成制剂。
8.一种如权利要求1-6任一项所述中药组合物在制备治疗膝骨关节炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210572729.0A CN114796325A (zh) | 2022-05-25 | 2022-05-25 | 一种治疗膝骨关节炎的中药组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210572729.0A CN114796325A (zh) | 2022-05-25 | 2022-05-25 | 一种治疗膝骨关节炎的中药组合物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114796325A true CN114796325A (zh) | 2022-07-29 |
Family
ID=82518047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210572729.0A Pending CN114796325A (zh) | 2022-05-25 | 2022-05-25 | 一种治疗膝骨关节炎的中药组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114796325A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116196379A (zh) * | 2023-03-31 | 2023-06-02 | 刘威 | 一种治疗人工膝关节置换术后疼痛及改善功能的中药组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679756A (zh) * | 2005-01-06 | 2005-10-12 | 贵州富华药业有限责任公司 | 治疗骨质疏松症的缓释制剂 |
CN107854683A (zh) * | 2017-12-25 | 2018-03-30 | 河南中医药大学 | 一种治疗湿热痹阻型膝骨关节炎的膏药 |
-
2022
- 2022-05-25 CN CN202210572729.0A patent/CN114796325A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679756A (zh) * | 2005-01-06 | 2005-10-12 | 贵州富华药业有限责任公司 | 治疗骨质疏松症的缓释制剂 |
CN107854683A (zh) * | 2017-12-25 | 2018-03-30 | 河南中医药大学 | 一种治疗湿热痹阻型膝骨关节炎的膏药 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116196379A (zh) * | 2023-03-31 | 2023-06-02 | 刘威 | 一种治疗人工膝关节置换术后疼痛及改善功能的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109966413A (zh) | 一种用于治疗化疗药物所致的周围神经病变的中药外用制剂 | |
CN109453460A (zh) | 药石热敷灸基质、含有其的中药组合物及制备方法 | |
CN114796325A (zh) | 一种治疗膝骨关节炎的中药组合物及其制备方法与应用 | |
CN103830482B (zh) | 一种治疗脑卒中的中药制剂及制备方法 | |
CN107412640B (zh) | 一种用于辅助针灸理疗的外用药膏 | |
CN102488784A (zh) | 一种治疗腰疼的中药组合物 | |
CN104547736A (zh) | 一种治疗甲状腺肿的药物 | |
CN104147261B (zh) | 一种治疗风湿性关节炎的中药制剂 | |
CN101983682A (zh) | 一种女性更年期综合症的治疗药物 | |
CN112043799A (zh) | 一种治疗痛风的口服药物及其制备方法 | |
CN112245494A (zh) | 一种治疗痛风的外用药物及其制备方法 | |
CN104491324A (zh) | 一种患者术后用活血通络气雾剂 | |
CN104887970A (zh) | 一种针灸理疗外用药膏 | |
CN104547384A (zh) | 一种治疗百草枯中毒的口服液及制备方法 | |
CN110496200A (zh) | 一种治疗肺结核的中药组合物及其制备方法和应用 | |
CN116492412B (zh) | 一种治疗血虚络阻证末梢神经炎的中药组合物 | |
CN117414351B (zh) | 用于治疗脾肾阳虚便秘的中药贴剂及其制备方法和应用 | |
CN109125450B (zh) | 一种治疗银屑病的中药组合物及其用途 | |
CN112972611A (zh) | 一种治疗溶血性贫血的药物组合物及其应用 | |
CN105079661A (zh) | 一种治疗便血的中药组合物 | |
CN104042908A (zh) | 一种治疗妇女更年期综合症的中药组合物 | |
CN104524157B (zh) | 一种治疗瘿病的中药制剂 | |
CN117653695A (zh) | 一种治疗皮痹的中药组合物 | |
CN115487261A (zh) | 一种用于治疗风湿骨痛疮痈肿毒的药酒及其制备方法 | |
CN103316258B (zh) | 一种治疗婴幼儿阴道炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220729 |